Pacira BioSciences, Inc. (PCRX)
PCRX Stock Price Chart
Explore Pacira BioSciences, Inc. interactive price chart. Choose custom timeframes to analyze PCRX price movements and trends.
PCRX Company Profile
Discover essential business fundamentals and corporate details for Pacira BioSciences, Inc. (PCRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Feb 2011
Employees
788.00
Website
https://www.pacira.comCEO
Frank D. Lee
Description
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
PCRX Financial Timeline
Browse a chronological timeline of Pacira BioSciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.64, while revenue estimate is $191.06m.
Earnings released on 30 Apr 2026
EPS came in at $0.60 falling short of the estimated $0.61 by -1.64%, while revenue for the quarter reached $177.38m , beating expectations by +3.25%.
Earnings released on 26 Feb 2026
EPS came in at $0.57 falling short of the estimated $0.85 by -32.94%, while revenue for the quarter reached $196.87m , missing expectations by -1.73%.
Earnings released on 6 Nov 2025
EPS came in at $0.70 surpassing the estimated $0.65 by +7.69%, while revenue for the quarter reached $179.52m , missing expectations by -11.10%.
Earnings released on 5 Aug 2025
EPS came in at $0.74 surpassing the estimated $0.72 by +2.78%, while revenue for the quarter reached $181.10m , missing expectations by -0.70%.
Earnings released on 8 May 2025
EPS came in at $0.62 surpassing the estimated $0.57 by +8.77%, while revenue for the quarter reached $168.92m , missing expectations by -9.90%.
Earnings released on 27 Feb 2025
EPS came in at $0.91 surpassing the estimated $0.78 by +16.67%, while revenue for the quarter reached $187.25m , beating expectations by +1.01%.
Earnings released on 6 Nov 2024
EPS came in at $0.79 surpassing the estimated $0.72 by +9.72%, while revenue for the quarter reached $168.57m , missing expectations by -6.08%.
Earnings released on 30 Jul 2024
EPS came in at $0.89 surpassing the estimated $0.73 by +21.92%, while revenue for the quarter reached $178.02m , beating expectations by +3.20%.
Earnings released on 7 May 2024
EPS came in at $0.62 falling short of the estimated $0.64 by -3.13%, while revenue for the quarter reached $167.12m , beating expectations by +1.07%.
Earnings released on 29 Feb 2024
EPS came in at $0.89 matching the estimated $0.89, while revenue for the quarter reached $181.24m , missing expectations by -0.23%.
Earnings released on 2 Nov 2023
EPS came in at $0.72 falling short of the estimated $0.84 by -14.29%, while revenue for the quarter reached $163.93m , missing expectations by -8.81%.
Earnings released on 2 Aug 2023
EPS came in at $0.78 falling short of the estimated $0.81 by -3.70%, while revenue for the quarter reached $169.47m , missing expectations by -2.94%.
Earnings released on 3 May 2023
EPS came in at $0.53 falling short of the estimated $0.60 by -11.67%, while revenue for the quarter reached $160.34m , beating expectations by +0.94%.
Earnings released on 28 Feb 2023
EPS came in at $0.80 matching the estimated $0.80, while revenue for the quarter reached $171.96m , beating expectations by +0.01%.
Earnings released on 3 Nov 2022
EPS came in at $0.64 falling short of the estimated $0.73 by -12.33%, while revenue for the quarter reached $167.47m , missing expectations by -0.51%.
Earnings released on 3 Aug 2022
EPS came in at $0.51 falling short of the estimated $0.85 by -40.00%, while revenue for the quarter reached $169.41m , missing expectations by -0.72%.
Earnings released on 4 May 2022
EPS came in at $0.64 falling short of the estimated $0.74 by -13.51%, while revenue for the quarter reached $157.99m , missing expectations by -1.09%.
Earnings released on 24 Feb 2022
EPS came in at $0.97 surpassing the estimated $0.83 by +16.87%, while revenue for the quarter reached $159.19m , beating expectations by +1.86%.
Earnings released on 3 Nov 2021
EPS came in at $0.72 surpassing the estimated $0.66 by +9.09%, while revenue for the quarter reached $127.72m , missing expectations by -9.09%.
Earnings released on 3 Aug 2021
EPS came in at $0.77 surpassing the estimated $0.76 by +1.32%, while revenue for the quarter reached $135.59m , beating expectations by +2.77%.
PCRX Stock Performance
Access detailed PCRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
